Talk:Lenvatinib

This is the talk page for discussing improvements to the Lenvatinib article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Lenvatinib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Melanoma Study

There is a study with E7080 for Melanoma now as well: http://www.clinicaltrials.gov/ct2/show/study/NCT01136967 —Preceding unsigned comment added by 212.23.103.38 (talk) 12:53, 21 February 2011 (UTC)[reply]

Why is it a multiple kinase inhibitor

What is it about the structure or shape of the molecule that makes it a multiple kinase inhibitor ? - Rod57 (talk) 16:59, 14 December 2016 (UTC)[reply]

Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization says (with diagram) "Co-crystal structure analysis demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-“in” conformation. These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors." - (quinoline is the 2 adjacent rings on the LHS, cyclopropane is the triangle on the RHS). Suggests that to some extent it acts as an ATP mimetic. - Rod57 (talk) 18:31, 14 December 2016 (UTC)[reply]